Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. 今日北醫
  4. 2026年03月號
  5. 萬芳醫院指出攝護腺癌治療新突破——熱治療輔助療法,研究顯示8年無復發率提升至98%
 
  • Details
Options

萬芳醫院指出攝護腺癌治療新突破——熱治療輔助療法,研究顯示8年無復發率提升至98%

Type
other
Date Issued
2026-03-14
Author(s)
萬芳醫院  
Subjects
今日北醫
Abstract
攝護腺癌是中高齡男性常見癌症之一,早期症狀與攝護腺肥大相似,往往延誤診斷。萬芳醫院放射腫瘤科吳正友醫師指出,癌症治療已邁入整合精準醫療時代。於「2025國際腫瘤熱治療年會」(ICHO)中,日本研究顯示,針對中高風險攝護腺癌患者,在標準治療基礎上加上腫瘤熱治療,8年無復發率可由87%提升至98%,顯示熱治療在整合療法中具潛在臨床價值。
URI
https://203.71.86.71/handle/123456789/8257
File(s)
Loading...
Thumbnail Image
Name

20260306.pdf

Size

269.23 KB

Format

Adobe PDF

Checksum

(MD5):7af64f1861255d20ab8125c300f540c9

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback